Inclusion Criteria:

• Must be 18 years of age or older with histologic diagnosis of soft tissue sarcoma
• Must have disease not suitable for curative resection
• Must have failed >1 first line treatment with evidence of progression. Adjuvant therapy does not count as 1st line therapy unless recurrence occurs within 6 months of administration
• Must have ability to understand and the willingness to sign a written informed consent document
• Must have Eastern Cooperative Oncology Group (ECOG) performance status of < 2
• Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
• At least 4 weeks have passed since the last chemotherapy, immunotherapy, or radiation therapy
• There must be measurable disease outside the radiotherapy fields or progression of the indicator lesions within the field since the completion of the radiotherapy
• Must have a life expectancy of greater than 12 weeks
• Must have clinical laboratory values at screening as defined below:
• Hemoglobin >9 g/dL,
• Absolute neutrophil count >1500/mm3,
• Platelet count >100,000/mm3,
• Creatinine <1.5 X ULN,
• Bilirubin <1.5 X ULN,
• Asparate aminotransferase and alanine aminotransferase <2.5 X ULN (<5 X ULN in presence of liver metastases)

Exclusion Criteria:

• Female patients who are pregnant or breast feeding
• Patients of childbearing potential not using or not willing to use a barrier method of contraception

• Prior malignancy other than soft tissue sarcoma (STS) within the last 5 yrs with the exception of:

  • Adequately treated in situ carcinoma of the cervix uteri;
  • Basal or squamous cell carcinoma of the skin
• Presence of a clinically significant and uncontrolled infection
• Presence of >Grade 2 neuropathy
• Symptomatic central nervous system metastases within last 8 weeks or on corticosteroids for CNS symptom management
• Presence of clinically significant arrythmias
• Presence of a serious concurrent illness or other conditions (e.g., psychological, family, sociological, or geographical circumstances) that do not permit adequate follow-up and compliance with the protocol
• History of severe hypersensitivity reactions to taxanes or cremaphore in spite of premedication
• Use of any investigational agents within 4 weeks prior to the first dose of study drug(s)
• Major surgery within 2 weeks of screening
• Radiation treatment in past >25% of bone marrow